CN114026126B - 抗半乳糖凝集素-9抗体及其用途 - Google Patents

抗半乳糖凝集素-9抗体及其用途 Download PDF

Info

Publication number
CN114026126B
CN114026126B CN202080047488.7A CN202080047488A CN114026126B CN 114026126 B CN114026126 B CN 114026126B CN 202080047488 A CN202080047488 A CN 202080047488A CN 114026126 B CN114026126 B CN 114026126B
Authority
CN
China
Prior art keywords
galectin
antibody
seq
tumor
months
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080047488.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN114026126A (zh
Inventor
S·小出
G·米勒
A·小出
L·陈
A·菲利波维奇
E·艾伦科
J·博伦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pure Technology Lyt Co ltd
New York University NYU
Original Assignee
Pure Technology Lyt Co ltd
New York University NYU
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pure Technology Lyt Co ltd, New York University NYU filed Critical Pure Technology Lyt Co ltd
Priority to CN202411238025.5A priority Critical patent/CN119033928A/zh
Publication of CN114026126A publication Critical patent/CN114026126A/zh
Application granted granted Critical
Publication of CN114026126B publication Critical patent/CN114026126B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57525—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the liver or pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5752—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the lungs
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57535—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the large intestine, e.g. colon, rectum or anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4724—Lectins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Gastroenterology & Hepatology (AREA)
CN202080047488.7A 2019-05-01 2020-05-01 抗半乳糖凝集素-9抗体及其用途 Active CN114026126B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202411238025.5A CN119033928A (zh) 2019-05-01 2020-05-01 抗半乳糖凝集素-9抗体及其用途

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962841732P 2019-05-01 2019-05-01
US62/841,732 2019-05-01
PCT/US2020/031181 WO2020223702A1 (en) 2019-05-01 2020-05-01 Anti-galectin-9 antibodies and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202411238025.5A Division CN119033928A (zh) 2019-05-01 2020-05-01 抗半乳糖凝集素-9抗体及其用途

Publications (2)

Publication Number Publication Date
CN114026126A CN114026126A (zh) 2022-02-08
CN114026126B true CN114026126B (zh) 2024-09-27

Family

ID=73029403

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202080047488.7A Active CN114026126B (zh) 2019-05-01 2020-05-01 抗半乳糖凝集素-9抗体及其用途
CN202411238025.5A Pending CN119033928A (zh) 2019-05-01 2020-05-01 抗半乳糖凝集素-9抗体及其用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202411238025.5A Pending CN119033928A (zh) 2019-05-01 2020-05-01 抗半乳糖凝集素-9抗体及其用途

Country Status (8)

Country Link
US (2) US20220185896A1 (https=)
EP (1) EP3962954A4 (https=)
JP (1) JP7581238B2 (https=)
CN (2) CN114026126B (https=)
AU (1) AU2020266677A1 (https=)
CA (1) CA3138863A1 (https=)
SG (1) SG11202112112UA (https=)
WO (2) WO2020223704A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3080120C (en) 2017-10-27 2023-11-21 New York University Anti-galectin-9 antibodies and uses thereof
JP7581238B2 (ja) * 2019-05-01 2024-11-12 ニューヨーク・ユニバーシティ 抗ガレクチン９抗体およびその使用
WO2022109299A1 (en) * 2020-11-20 2022-05-27 New York University Anti-galectin-9 antibodies and therapeutic uses thereof
CA3217833A1 (en) * 2021-04-30 2022-11-03 Puretech Lyt, Inc. Combination of anti-galectin-9 antibodies and chemotherapeutics for use in cancer therapy
US20240190970A1 (en) * 2021-04-30 2024-06-13 Puretech Lyt, Inc. Anti-galectin-9 antibodies and therapeutic uses thereof
MX2024004012A (es) * 2021-10-01 2024-07-01 Puretech Lyt Inc Anticuerpos anti-galectina-9 y usos terapéuticos de estos.
KR20250029919A (ko) * 2022-06-29 2025-03-05 퓨어테크 엘와이티, 아이엔씨. 갈렉틴-9를 억제하는 항체를 사용한 혈액학적 악성종양의 치료
CN120585880B (zh) * 2025-08-07 2025-12-09 四川大学华西医院 一种用于预防和/或治疗前列腺癌的联合用药物，其用途及药物组合物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103314102A (zh) * 2010-12-09 2013-09-18 株式会社嘉尔药物 分泌半乳糖凝集素9的细胞、其制造方法及其用途
CN107074936A (zh) * 2014-06-06 2017-08-18 里尔科学技术大学 抗半乳糖凝集素9并且是调节性t细胞抑制活性的抑制剂的抗体

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2591786B1 (en) * 2003-10-16 2017-04-12 Cancure Limited Immunomodulating compositions and uses therefor
CN101120021A (zh) * 2004-12-31 2008-02-06 基因技术公司 结合br3的多肽及其用途
EP1973951A2 (en) * 2005-12-02 2008-10-01 Genentech, Inc. Binding polypeptides with restricted diversity sequences
CN101977934B (zh) * 2008-01-18 2014-09-17 健泰科生物技术公司 用于靶向k63连接的多聚遍在蛋白的方法和组合物
MX2011000655A (es) * 2008-07-18 2011-03-21 Oragenics Inc Composiciones para la deteccion y tratamiento de cancer colorrectal.
WO2012064836A1 (en) * 2010-11-10 2012-05-18 Genentech, Inc. Methods and compositions for neural disease immunotherapy
US10837966B2 (en) * 2014-11-04 2020-11-17 Dana-Farber Cancer Institute, Inc. Anti-galectin antibody biomarkers predictive of anti-immune checkpoint and anti-angiogenesis responses
US10294294B2 (en) * 2015-09-10 2019-05-21 Albert Einstein College Of Medicine Synthetic antibodies to BAX and uses thereof
WO2017202962A1 (en) * 2016-05-24 2017-11-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of non small cell lung cancer (nsclc) that coexists with chronic obstructive pulmonary disease (copd)
CA3066747A1 (en) * 2017-06-27 2019-01-03 Novartis Ag Dosage regimens for anti-tim-3 antibodies and uses thereof
WO2019036031A2 (en) * 2017-08-17 2019-02-21 Nektar Therapeutics IMMUNOTHERAPEUTIC METHOD FOR TUMOR TREATMENT
CA3080120C (en) * 2017-10-27 2023-11-21 New York University Anti-galectin-9 antibodies and uses thereof
AU2020247993A1 (en) * 2019-03-25 2021-11-18 New York University Anti-Galectin-9 antibodies and uses thereof
JP7581238B2 (ja) * 2019-05-01 2024-11-12 ニューヨーク・ユニバーシティ 抗ガレクチン９抗体およびその使用
US20220332832A1 (en) * 2019-08-01 2022-10-20 New York University Combined cancer therapy of anti-galectin-9 antibodies and chemotherapeutics
US20240287195A1 (en) * 2020-10-26 2024-08-29 Puretech Lyt, Inc. Anti-galectin-9 antibodies and uses thereof in the treatment of ocular melanoma
US20240043543A1 (en) * 2020-11-20 2024-02-08 New York University Anti-galectin-9 antibodies and therapeutic uses thereof
WO2022109299A1 (en) * 2020-11-20 2022-05-27 New York University Anti-galectin-9 antibodies and therapeutic uses thereof
CA3217833A1 (en) * 2021-04-30 2022-11-03 Puretech Lyt, Inc. Combination of anti-galectin-9 antibodies and chemotherapeutics for use in cancer therapy
US20240190970A1 (en) * 2021-04-30 2024-06-13 Puretech Lyt, Inc. Anti-galectin-9 antibodies and therapeutic uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103314102A (zh) * 2010-12-09 2013-09-18 株式会社嘉尔药物 分泌半乳糖凝集素9的细胞、其制造方法及其用途
CN107074936A (zh) * 2014-06-06 2017-08-18 里尔科学技术大学 抗半乳糖凝集素9并且是调节性t细胞抑制活性的抑制剂的抗体

Also Published As

Publication number Publication date
WO2020223704A1 (en) 2020-11-05
JP7581238B2 (ja) 2024-11-12
EP3962954A1 (en) 2022-03-09
EP3962954A4 (en) 2023-01-18
AU2020266677A1 (en) 2022-01-06
WO2020223702A1 (en) 2020-11-05
SG11202112112UA (en) 2021-11-29
JP2022531408A (ja) 2022-07-06
CA3138863A1 (en) 2020-11-05
US20220185896A1 (en) 2022-06-16
CN114026126A (zh) 2022-02-08
US20220178930A1 (en) 2022-06-09
CN119033928A (zh) 2024-11-29

Similar Documents

Publication Publication Date Title
CN114026126B (zh) 抗半乳糖凝集素-9抗体及其用途
AU2020319899B2 (en) Combined cancer therapy of anti-galectin-9 antibodies and chemotherapeutics
US20240043543A1 (en) Anti-galectin-9 antibodies and therapeutic uses thereof
CN116782934A (zh) 抗半乳糖凝集素9抗体及其在治疗眼部黑素瘤中的用途
US20240109968A1 (en) Anti-galectin-9 antibodies and therapeutic uses thereof
US20240182583A1 (en) Combination of anti-galectin-9 antibodies and chemotherapeutics for use in cancer therapy
US20240190970A1 (en) Anti-galectin-9 antibodies and therapeutic uses thereof
HK40069657A (en) Anti-galectin-9 antibodies and uses thereof
HK40069657B (zh) 抗半乳糖凝集素-9 抗体及其用途
CN117500522A (zh) 抗半乳糖凝集素-9抗体及其治疗用途
HK40098226A (zh) 抗半乳糖凝集素9抗体及其在治疗眼部黑素瘤中的用途
KR20240082393A (ko) 항-갈렉틴-9 항체 및 이의 치료적 용도
HK40108543A (zh) 在癌症疗法中使用的抗半乳糖凝集素-9抗体和化疗剂的组合
CN118251234A (zh) 抗半乳糖凝集素-9抗体及其治疗用途
HK40074716A (en) Combined cancer therapy of anti-galectin-9 antibodies and chemotherapeutics
CN117580589A (zh) 在癌症疗法中使用的抗半乳糖凝集素-9抗体和化疗剂的组合
HK40112915A (zh) 抗半乳糖凝集素-9抗体及其治疗用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40069657

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant